Investor news
07.11.2011

On 5 November, NeuroSearch participated in the Huntington Disease Clinical
Research Symposium, which was held in Indianapolis, USA. This fifth annual
symposium was organised by the Huntington Study Group, which takes part in the
coordination of clinical studies within Huntington's disease.

At the symposium, NeuroSearch presented studies describing the compound's
mechanism of action under the title:

Pridopidine: modulating the direct and indirect pathways controlling movement

NeuroSearch has made an unrestricted grant to Université Claude Bernard Lyon I
to support studies of the socio economic burden related to Huntington's
disease. This work is referred to as the Global Huntington's Disease Burden,
and partial results from the study were presented under the title:

Burden of Huntington's disease in USA

Both presentations are available on the company's website via the following
link.

Contact person
Mads P. G. Korsgaard, Manager, Investor Relations & Corporate Communications,
telephone: +45 4460 8309


About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil®, a unique drug in Phase III for the
treatment of the motor symptoms of Huntington's disease.

Presse.03-11 - NeuroSearch presented at the HDCRS - uk.pdf